Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Common Stock, Series A	Common Stock, Series B	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interests	Total
BALANCE at Jul. 31, 2018	$ 8	$ 118	$ 103,636	$ (1,108)	$ 4,043	$ 9,427	$ 116,124
BALANCE, SHARES at Jul. 31, 2018	787,163	11,762,346
Net loss				(1,502)		136	(1,366)
Adoption effect of ASU 2016-01				(39)	39
Purchase of Class B Common Shares		$ 12	8,630				8,642
Purchase of Class B Common Shares, shares		1,254,200
Stock based compensation to Board of Directors			107				107
Stock based compensation to Board of Directors, shares		12,609
Stock based compensation		$ 1	64				65
Stock based compensation, Shares		70,718
Stock options exercised			163				163
Stock options exercised, shares		33,196
Debt discount on convertible debt			71				71
Capital contribution from noncontrolling interest						4,587	4,587
Foreign currency translation adjustment					(2)		(2)
BALANCE at Jan. 31, 2019	$ 8	$ 131	112,671	(2,649)	4,080	14,150	128,391
BALANCE, SHARES at Jan. 31, 2019	787,163	13,133,069
BALANCE at Oct. 31, 2018	$ 8	$ 118	103,784	(1,628)	4,160	9,243	115,685
BALANCE, SHARES at Oct. 31, 2018	787,163	11,786,397
Net loss				(1,021)		320	(701)
Purchase of Class B Common Shares		$ 12	8,630				8,642
Purchase of Class B Common Shares, shares		1,254,200
Stock based compensation to Board of Directors			107				107
Stock based compensation to Board of Directors, shares		12,609
Stock based compensation		$ 1	34				35
Stock based compensation, Shares		70,718
Stock options exercised			45				45
Stock options exercised, shares		9,145
Debt discount on convertible debt			71				71
Capital contribution from noncontrolling interest						4,587	4,587
Foreign currency translation adjustment					(80)		(80)
BALANCE at Jan. 31, 2019	$ 8	$ 131	112,671	(2,649)	4,080	14,150	128,391
BALANCE, SHARES at Jan. 31, 2019	787,163	13,133,069
BALANCE at Jul. 31, 2019	$ 8	$ 131	112,898	(5,840)	3,784	13,783	124,764
BALANCE, SHARES at Jul. 31, 2019	787,163	13,142,502
Net loss				(2,851)		(129)	(2,980)
Stock based compensation to Board of Directors			208				208
Stock based compensation to Board of Directors, shares		12,609
Stock based compensation			203				203
Stock based compensation, Shares		20,863
Shares issued for convertible debt		$ 18	15,650				15,668
Shares issued for convertible debt, shares		1,849,749
Shares withheld for payroll taxes			(116)				(116)
Shares withheld for payroll taxes, shares		(5,238)
Conversion of LipoMedix Bridge Notes						200	200
Foreign currency translation adjustment					(28)		(28)
BALANCE at Jan. 31, 2020	$ 8	$ 149	128,843	(8,691)	3,756	13,854	137,919
BALANCE, SHARES at Jan. 31, 2020	787,163	15,020,485
BALANCE at Oct. 31, 2019	$ 8	$ 149	128,642	(7,438)	3,790	13,811	138,962
BALANCE, SHARES at Oct. 31, 2019	787,163	14,997,251
Net loss				(1,253)		(75)	(1,328)
Stock based compensation to Board of Directors			208				208
Stock based compensation to Board of Directors, shares		12,609
Stock based compensation			109				109
Stock based compensation, Shares		15,863
Shares withheld for payroll taxes			(116)				(116)
Shares withheld for payroll taxes, shares		(5,238)
Conversion of LipoMedix Bridge Notes						118	118
Foreign currency translation adjustment					(34)		(34)
BALANCE at Jan. 31, 2020	$ 8	$ 149	$ 128,843	$ (8,691)	$ 3,756	$ 13,854	$ 137,919
BALANCE, SHARES at Jan. 31, 2020	787,163	15,020,485